Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003542 · ClinicalTrials.gov registry record · Phase 1
Interferon Alfa in Treating Patients With Advanced Kidney Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT00003542: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003542 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003542, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of interferon alfa in treating patients with advanced kidney cancer.
Interventions
- BIOLOGICAL pegylated interferon alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 1998-05 |
| Est. Completion | 2004-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003542
The ClinicalTrials.gov registry entry for NCT00003542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pegylated interferon alfa is the first listed.
NCT00003542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003542 about?
NCT00003542 is a clinical study titled "Interferon Alfa in Treating Patients With Advanced Kidney Cancer". RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of interferon alfa in treating patients with advanced kidney cancer.
What is the current status of trial NCT00003542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 1998-05. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00003542?
The interventions under investigation include: pegylated interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003542?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.